Show simple item record

dc.contributor.authorPriotto, Gerardo
dc.contributor.authorKabakyenga, Jerome
dc.contributor.authorPinoges, Loretxu
dc.contributor.authorRuiz, Aria
dc.contributor.authorEriksson, Therese
dc.contributor.authorCoussement s, Frangois
dc.contributor.authorNgambe, Tharcise
dc.contributor.authorTaylor, Walter R. J.
dc.contributor.authorPerea, William
dc.contributor.authorGuthmann, Jean-Paul
dc.contributor.authorOlliaro, Piero
dc.contributor.authorLegros, Dominique
dc.date.accessioned2022-04-06T15:57:53Z
dc.date.available2022-04-06T15:57:53Z
dc.date.issued2003
dc.identifier.citationPriotto, G., Kabakyenga, J., Pinoges, L., Ruiz, A., Eriksson, T., Coussement, F., ... & Legros, D. (2003). Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial. Transactions of the Royal Society of Tropical Medicine and Hygiene, 97(3), 325-330.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/1722
dc.description.abstractDrug-resistant malaria is spreading in Africa. The few available drugs might be safeguarded if combined with an artemisinin derivative. We investigated the efficacy, safety, and tolerability of 2 combinations of artesunate with sulfadoxine-pyrimethamine (SP) in a mesoendemic region in Uganda with SP resis tance, from September 1999 to June 2000. In a randomized, double-blind, placebo-controlled trial, 420 children aged 6-59 months with uncomplicated Plasmodium falciparum malaria were assigned SP alone (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine) or combined with artesunate (AS; 4 mg/kg/d) for either 1 d (SPAS1) or 3 d (SPAS3). Children were followed-up for 28 d. Day 14 cure rates were 84.6% (99/117) with SPAS3 and 61.9% (73/118) with SPAS1 compared with 55.8% (86/154) with SP. Corresponding day 28 results were 74.4% (87/117) and 45.2% (52/115) compared with 40.5% (62/153). A significant improvement was obtained with the addition of 3 d, but not 1 d, of artesunate (risk ratio [RR] = 1.5, 95% CI 1.3-1.8 at 14 d and RR = 1.8, 95% CI 1.5-2.3 at 28 d). Both AS regimens achieved significantly faster parasite clearance and lower gametocyte carriage. All drug regi mens were well tolerated, but SP alone was ineffective. Treatment efficacy improved with SPAS3 but the cure rate at day 28 was modest. The combinations were well tolerated and safe. In areas where SP resistance is prevalent other combinations should be considered.en_US
dc.language.isoen_USen_US
dc.publisherROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENEen_US
dc.subjectMalariaen_US
dc.subjectPlasmodiumfalciparumen_US
dc.subjectChemotherapyen_US
dc.subjectArtesunateen_US
dc.subjectSulfadoxine-pyrimethamineen_US
dc.subjectUgandaen_US
dc.titleArtesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trialen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record